PTC Therapeutics Inc (PTCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PTC Therapeutics Inc (PTCT) has a cash flow conversion efficiency ratio of 0.167x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-34.27 Million) by net assets ($-205.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PTC Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how PTC Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PTC Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
PTC Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PTC Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GEM CO. LTD SP.GDR/10 A
F:3730
|
N/A |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
-0.001x |
|
Keda Clean Energy Co Ltd
SHG:600499
|
0.094x |
|
Home BancShares Inc
NYSE:HOMB
|
0.030x |
|
Sinopec Oilfield Service Corp
SHG:600871
|
0.100x |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
0.197x |
|
Jfrog Ltd
NASDAQ:FROG
|
0.057x |
|
BRF SA ADR
NYSE:BRFS
|
0.142x |
Annual Cash Flow Conversion Efficiency for PTC Therapeutics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of PTC Therapeutics Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see PTC Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-205.31 Million | $711.20 Million | -3.464x | -3632.12% |
| 2024-12-31 | $-1.10 Billion | $-107.69 Million | 0.098x | -49.33% |
| 2023-12-31 | $-818.55 Million | $-158.42 Million | 0.194x | -81.17% |
| 2022-12-31 | $-347.09 Million | $-356.65 Million | 1.028x | +100.59% |
| 2021-12-31 | $1.44 Million | $-251.33 Million | -174.779x | -43306.93% |
| 2020-12-31 | $481.98 Million | $-194.07 Million | -0.403x | -142.61% |
| 2019-12-31 | $594.33 Million | $-98.64 Million | -0.166x | -110.59% |
| 2018-12-31 | $350.73 Million | $-27.64 Million | -0.079x | -22.52% |
| 2017-12-31 | $156.44 Million | $-10.06 Million | -0.064x | +92.57% |
| 2016-12-31 | $119.58 Million | $-103.57 Million | -0.866x | -107.89% |
| 2015-12-31 | $298.47 Million | $-124.34 Million | -0.417x | -117.09% |
| 2014-12-31 | $298.47 Million | $-57.27 Million | -0.192x | +44.16% |
| 2013-12-31 | $136.54 Million | $-46.92 Million | -0.344x | -113.76% |
| 2012-12-31 | $-19.19 Million | $-47.93 Million | 2.497x | +2768.93% |
| 2011-12-31 | $-238.60 Million | $-20.77 Million | 0.087x | -- |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more